Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103 GBX | 0.00% | -0.48% | +18.39% |
04-02 | Roadside shares suspended; Adnams looks for funds | AN |
03-21 | Diaceutics upgrades diagnositc commercialisation platform, DXRX | AN |
Sales 2023 * | 23.89M 29.83M 2.39B | Sales 2024 * | 29.61M 36.98M 2.96B | Capitalization | 86.99M 109M 8.7B |
---|---|---|---|---|---|
Net income 2023 * | -1M -1.25M -100M | Net income 2024 * | -2M -2.5M -200M | EV / Sales 2023 * | 2.97 x |
Net cash position 2023 * | 16.13M 20.14M 1.61B | Net cash position 2024 * | 13.48M 16.84M 1.35B | EV / Sales 2024 * | 2.48 x |
P/E ratio 2023 * |
-61
x | P/E ratio 2024 * |
-54.5
x | Employees | 151 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 65.46% |
Latest transcript on Diaceutics PLC
1 week | -0.48% | ||
Current month | -3.74% | ||
1 month | -0.96% | ||
3 months | +11.96% | ||
6 months | +23.35% | ||
Current year | +18.39% |
Managers | Title | Age | Since |
---|---|---|---|
Ryan Keeling
CEO | Chief Executive Officer | 40 | 31/05/08 |
Nick Roberts
DFI | Director of Finance/CFO | - | 17/03/22 |
Julie Browne
COO | Chief Operating Officer | - | 14/03/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Graham Paterson
BRD | Director/Board Member | - | 30/09/23 |
Deborah Davis
CHM | Chairman | 61 | 03/01/21 |
Peter Keeling
BRD | Director/Board Member | 63 | 31/12/04 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 103 | 0.00% | 25,020 |
25/04/24 | 103 | 0.00% | 5,041 |
24/04/24 | 103 | 0.00% | 14,948 |
23/04/24 | 103 | -0.48% | 66,366 |
22/04/24 | 103.5 | 0.00% | 7,298 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.39% | 108M | |
+5.21% | 4.03B | |
+20.98% | 1.89B | |
0.00% | 1.84B | |
-3.22% | 1.71B | |
+3.13% | 1.63B | |
-16.98% | 1.58B | |
-23.29% | 1.36B | |
-7.67% | 1.16B | |
-4.66% | 1.05B |
- Stock Market
- Equities
- DXRX Stock